Protambbody
Financiado
Proteasomal degradation of toxic intracellular amyloid-beta protein by nanobody-...
Proteasomal degradation of toxic intracellular amyloid-beta protein by nanobody-enabled proximity to ubiquitin ligase
The amyloid-beta (Aβ) protein arises from the sequential proteolytic cleavage of Aβ precursor protein (APP). The accumulation of Aβ oligomers has been regarded as the causal factor of Alzheimer’s disease (AD). Basal metabolic prod...
The amyloid-beta (Aβ) protein arises from the sequential proteolytic cleavage of Aβ precursor protein (APP). The accumulation of Aβ oligomers has been regarded as the causal factor of Alzheimer’s disease (AD). Basal metabolic production of the Aβ peptide is typical in healthy people, and its production rate is normally lower than its rate of clearance. In AD, the uncontrolled accumulation of toxic forms of Aβ stemming from problems in its clearance and degradation results in memory loss, chronic neuroinflammation and neurodegeneration. AD is a leading cause of disability and death both in Europe and the world, and currently has no cure or clinically-proven disease-modifying therapies.
There are over 10 million new cases of dementia each year worldwide (up to 80% of which are due to AD), implying one new case every 3.2 seconds. In Europe, about 10 million people currently suffer from this disease and about 50 million in the world; with these estimates projected to double by 2050. Thus, the identification of novel disease-modifying therapies has become very critical to eradicating AD from Europe and the world. My project proposes a radically novel approach in the AD field of utilizing the body’s cellular waste disposal system to selectively degrade Aβ peptide, the causative agent of AD. This is in sharp contrast to the current approach of immunization against the Aβ peptide, which has repeatedly failed to yield any cure or disease-modifying therapies for AD.
This project will aim to identify the specific cytotoxic Aβ peptides responsible for neuroinflammation and neurodegeneration in human induced pluripotent stem cells and target these peptides for degradation by the ubiquitin proteasome system. Emphasis will be on the cytotoxic Aβ peptides of intracellular origin as emerging targets in AD. This research will be conducted at the University of Helsinki, Finland, followed by a non-academic placement at Roche Diagnostics GmbH.
ver más
Duración del proyecto: 36 meses
Fecha Inicio: 2022-06-08
Fecha Fin: 2025-06-30
Fecha Fin: 2025-06-30
Línea de financiación: concedida
El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2022-06-08
Línea de financiación objetivo
El proyecto se financió a través de la siguiente ayuda:
HORIZON-MSCA-2021-PF-01-01:
MSCA Postdoctoral Fellowships 2021
Cerrada
hace 3 años
Presupuesto
El presupuesto total del proyecto asciende a
269K€
Líder del proyecto
HELSINGIN YLIOPISTO
No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico
TRL
4-5
Perfil tecnológico
TRL
4-5
N.D. |
Participante